-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the third quarter of this year, Hillhouse Capital mainly reduced positions in the secondary market, but did not increase positions, and it disappeared from such pharmaceutical companies as Kailaiying, Tigermed, and Aier Ophthalmology
.
It is understood that in the past, Hillhouse has attached great importance to the pharmaceutical sector, but in the third quarter of this year, it has significantly reduced its holdings in the pharmaceutical sector, which has also caused market speculation
.
In this regard, Hillhouse said that although Hillhouse’s secondary market investment team has recently adjusted its holdings of several high-valued and mature companies in the A-share market, some of the companies that have reduced their holdings are actually subdivided in CXO.
Hillhouse still has an extensive and in-depth layout for pharmaceutical and medical companies in the A-share and Hong Kong stock markets
.
Among them, biomedicine is still a strong position, and it continues to invest in pharmaceutical companies in the field of biotechnology
.
According to reports, Hillhouse Ventures, a subsidiary of the company, which focuses on early investment, has made nearly ten shots in the pharmaceutical field in the primary market in the third quarter alone, including companies such as Pengli Biological, Amador Biological, Huahui Anjian, and Etop Pharmaceuticals
.
The author has learned that Hillhouse has also deployed leading companies in cell therapy of different technical routes.
Its investment in Legend Bio, Beiheng Bio, Keji Pharmaceutical, and Reindeer Bio will use its focus on CAR that is closer to the clinic.
-T technology is currently conducting in-depth research on acute lymphoblastic leukemia, T cell malignancies, multiple myeloma, optic neuromyelitis and other diseases, and some products have entered clinical phase II and III for key registration
.
In the third quarter of this year, Hillhouse has invested in a number of companies in the field of cell therapy.
For example, Hillhouse Ventures led the investment in July, and Xingze Capital and Junshi Biotechnology participated in the investment of the new sharp gravel biology for tumor infiltration lymphocyte therapy; in August, Hillhouse Ventures Invested and invested in Shanghai Yuesai Biotechnology Co.
, Ltd.
, an enterprise in the field of pluripotent stem cell drug development
.
End of the third quarter, Hillhouse Capital's Liren excellent evergreen two private equity investment fund holdings biological, Franc Group, Hualan and other Antu
.
Hillhouse, as the cornerstone investor of Shamrock, subscribed for US$22 million in October
.
In addition, Hillhouse Capital also investigated pharmaceutical stocks such as Changchun Hi-tech in the third quarter of this year
.
It is understood that Hillhouse Capital frequently acts in the field of biomedicine
.
Except for the third quarter, in January this year, Hillhouse invested 80 million yuan in Kailaipu, a subsidiary of Dean Diagnostics Holdings, accounting for 7.
6% of the shares
.
In February, Hillhouse invested 503 million yuan to purchase 3.
46 million shares of Huada Gene at a price of 145 yuan per share, with a fixed increase and lock-up period of 6 months
.
On January 31, Luye Pharma also announced that it had signed a contract with Hillhouse NEV, a fund of Hillhouse Capital, to obtain HK$1.
25 billion in financing from Hillhouse Capital by way of private placement of new shares.
The issuance of new shares is a 10% premium to the closing price on the day of the signing of the agreement
.
In addition, Hillhouse Capital also obtained the transfer of part of the issued shares of Luye Pharmaceutical at the same price per share
.
The total amount of the two transactions is HK$2.
4 billion.
After the transaction is completed, Hillhouse Capital will hold 15.
60% of Luye Pharmaceutical
.
Hillhouse has also increased positions in BeiGene many times
.
Among them, on May 18, 2021, Hillhouse announced in the SEC the position of US stocks in the first quarter of 2021.
Among them, BeiGene became a major position in Hillhouse at that time
.
According to the industry, the investment in many pharmaceutical companies reflects Hillhouse's investment direction in 2021, which is to focus on cutting-edge biotechnology and continue to increase the size of the medical and health field
.
For a long time, based on the recognition of the great value of the field, Hillhouse insists on paying close attention to and holding key positions in biotechnology and medical equipment
.
.
It is understood that in the past, Hillhouse has attached great importance to the pharmaceutical sector, but in the third quarter of this year, it has significantly reduced its holdings in the pharmaceutical sector, which has also caused market speculation
.
In this regard, Hillhouse said that although Hillhouse’s secondary market investment team has recently adjusted its holdings of several high-valued and mature companies in the A-share market, some of the companies that have reduced their holdings are actually subdivided in CXO.
Hillhouse still has an extensive and in-depth layout for pharmaceutical and medical companies in the A-share and Hong Kong stock markets
.
Among them, biomedicine is still a strong position, and it continues to invest in pharmaceutical companies in the field of biotechnology
.
According to reports, Hillhouse Ventures, a subsidiary of the company, which focuses on early investment, has made nearly ten shots in the pharmaceutical field in the primary market in the third quarter alone, including companies such as Pengli Biological, Amador Biological, Huahui Anjian, and Etop Pharmaceuticals
.
The author has learned that Hillhouse has also deployed leading companies in cell therapy of different technical routes.
Its investment in Legend Bio, Beiheng Bio, Keji Pharmaceutical, and Reindeer Bio will use its focus on CAR that is closer to the clinic.
-T technology is currently conducting in-depth research on acute lymphoblastic leukemia, T cell malignancies, multiple myeloma, optic neuromyelitis and other diseases, and some products have entered clinical phase II and III for key registration
.
In the third quarter of this year, Hillhouse has invested in a number of companies in the field of cell therapy.
For example, Hillhouse Ventures led the investment in July, and Xingze Capital and Junshi Biotechnology participated in the investment of the new sharp gravel biology for tumor infiltration lymphocyte therapy; in August, Hillhouse Ventures Invested and invested in Shanghai Yuesai Biotechnology Co.
, Ltd.
, an enterprise in the field of pluripotent stem cell drug development
.
End of the third quarter, Hillhouse Capital's Liren excellent evergreen two private equity investment fund holdings biological, Franc Group, Hualan and other Antu
.
Hillhouse, as the cornerstone investor of Shamrock, subscribed for US$22 million in October
.
In addition, Hillhouse Capital also investigated pharmaceutical stocks such as Changchun Hi-tech in the third quarter of this year
.
It is understood that Hillhouse Capital frequently acts in the field of biomedicine
.
Except for the third quarter, in January this year, Hillhouse invested 80 million yuan in Kailaipu, a subsidiary of Dean Diagnostics Holdings, accounting for 7.
6% of the shares
.
In February, Hillhouse invested 503 million yuan to purchase 3.
46 million shares of Huada Gene at a price of 145 yuan per share, with a fixed increase and lock-up period of 6 months
.
On January 31, Luye Pharma also announced that it had signed a contract with Hillhouse NEV, a fund of Hillhouse Capital, to obtain HK$1.
25 billion in financing from Hillhouse Capital by way of private placement of new shares.
The issuance of new shares is a 10% premium to the closing price on the day of the signing of the agreement
.
In addition, Hillhouse Capital also obtained the transfer of part of the issued shares of Luye Pharmaceutical at the same price per share
.
The total amount of the two transactions is HK$2.
4 billion.
After the transaction is completed, Hillhouse Capital will hold 15.
60% of Luye Pharmaceutical
.
Hillhouse has also increased positions in BeiGene many times
.
Among them, on May 18, 2021, Hillhouse announced in the SEC the position of US stocks in the first quarter of 2021.
Among them, BeiGene became a major position in Hillhouse at that time
.
According to the industry, the investment in many pharmaceutical companies reflects Hillhouse's investment direction in 2021, which is to focus on cutting-edge biotechnology and continue to increase the size of the medical and health field
.
For a long time, based on the recognition of the great value of the field, Hillhouse insists on paying close attention to and holding key positions in biotechnology and medical equipment
.
